{
    "clinical_study": {
        "@rank": "146279", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "PF-06410293"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Active Comparator", 
                "description": "Adalimumab-EU"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Active Comparator", 
                "description": "Adalimumab-US"
            }
        ], 
        "brief_summary": {
            "textblock": "This healthy volunteers study will evaluate 210 subjects who will receive a single\n      sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European\n      Union).  This study will involve sampling and pharmacokinetics evaluation of drug levels\n      following administration of PF-06410293 and the licensed adalimumab products."
        }, 
        "brief_title": "Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female (non-childbearing potential).  Healthy is defined as no\n             clinically relevant abnormalities identified by a detailed medical history, full\n             physical examination including blood pressure, pulse, ECG, and laboratory testing.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant infectious, hematological, renal,\n             endocrine, pulmonary gastrointestinal, cardiovascular, hepatic psychiatric,\n             neurologic, autoimmune, or allergic disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870986", 
            "org_study_id": "B5381001", 
            "secondary_id": "REFLECTIONS B538-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "description": "40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.", 
                "intervention_name": "PF-06410293", 
                "intervention_type": "Biological", 
                "other_name": "adalimumab-Pfizer"
            }, 
            {
                "arm_group_label": "B", 
                "description": "40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.", 
                "intervention_name": "Humira (adalimumab-EU)", 
                "intervention_type": "Biological", 
                "other_name": "adalimumab (European Union)"
            }, 
            {
                "arm_group_label": "C", 
                "description": "40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.", 
                "intervention_name": "Humira (adalimumab-US)", 
                "intervention_type": "Biological", 
                "other_name": "adalimumab (United States)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Healthy Volunteers", 
            "Phase 1", 
            "PK", 
            "adalimumab", 
            "Single-dose", 
            "Immunology", 
            "Bioequivalence", 
            "Biosimilarity", 
            "Similarity."
        ], 
        "lastchanged_date": "February 13, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5381001&StudyName=Study%20Of%20PF-06410293%20And%20adalimumab%20In%20Healthy%20Subjects%20%28REFLECTIONS%20B538-01%29"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "B-1070"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Serum Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 43"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Time Point with Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 43"
            }, 
            {
                "measure": "Area under the Concentration-Time Curve (AUC) from Time Zero extrapolated to infinity (AUCInf)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 43"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of anti-adalimumab antibodies (ADA) and neutralizing antibodies (Nab)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 - Day 71"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Serum Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1- Day 43"
            }, 
            {
                "measure": "Area under the Concentration-Time Curve (AUC) time Zero to 2 weeks after Dosing", 
                "safety_issue": "No", 
                "time_frame": "Day 1- Day 43"
            }, 
            {
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Day 1- Day 43"
            }, 
            {
                "description": "Serum decay half-life is teh time for the serum concentration to decrease by one half", 
                "measure": "Serum Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 1- Day 43"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}